Bio/Pharma News

GSK Agrees to Sell Thrombosis Brands and Manufacturing Site to Aspen

October 02, 2013

GlaxoSmithKline?s sale of its thrombosis brands is part of a focus on its late-stage pipeline.

Merck Cuts 8,500 Positions, Moves Headquarters

October 01, 2013

Merck announced plans to reduce its workforce by 8,500 and move its headquarters in order to sharpen its commercial and R&D focus.

Ablynx And AbbVie Sign License Agreement For Anti-IL-6R Nanobody

September 27, 2013

Ablynx and AbbVie sign license agreement for Anti-IL-6R Nanobody, ALX-0061 to treat inflammatory diseases.

J&J's Janssen and PATH Partner to Develop Rilpivirine Formulation

September 27, 2013

J&J's Janssen and PATH partner to improve drug formulation that could help prevent HIV infection.

Merck & Co. Receives Complete Response Letter From FDA Regarding Sugammadex Sodium Injection

September 27, 2013

Merck & Co. has received a Complete Response Letter from FDA for the resubmission of its new drug application for sugammadex sodium injection.

GlaxoSmithKline Adopts Continuous Manufacturing for Preparation of Key Intermediate

September 25, 2013

Use of a continuous-flow reaction made it possible to scale up a highly exothermic reaction for the production of a key Suzuki−Miyaura coupling reagent.

GSK Responds to Patent Ruling Reversal on Lovaza

September 18, 2013

GSK reported that the Court of Appeals has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza.

AstraZeneca and Merck Enter License Agreement for Ovarian Cancer Therapy

September 18, 2013

AstraZeneca and Merck & Co. form a licensing agreement for Merck?s oral small-molecule drug for ovarian cancer.

Sanofi Withdraws NDA for Lixisenatide

September 18, 2013

Sanofi withdraws its new drug application (NDA) in the US for lixisenatide and plans to file a NDA in 2015.

Novartis Making Moves to Increase Biologics Manufacturing Capability

September 11, 2013

Novartis? half-billion dollar investment in a new biologics production plant in Singapore represents a strategic commitment to its growing biologics portfolio.